文献速递淋巴瘤

PEMD方案治疗初治早期非上呼吸道消化道或晚期结外NK/T细胞淋巴瘤的疗效与安全性

[Efficacy and safety of PEMD regimen in newly diagnosed early-stage non-upper respiratory digestive tract or advanced extranodal natural killer/T-cell lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

回顾性分析38例初治早期非上呼吸道消化道或晚期结外NK/T细胞淋巴瘤患者,接受PEMD方案诱导化疗,总有效率52.7%,2年及4年PFS率分别为34.2%和25.5%,主要不良反应为贫血(31例,81.6%)。

要点

  • PEMD方案治疗38例初治早期非上呼吸道消化道或晚期ENKTL,总有效率52.7%。
  • 2年及4年PFS率分别为34.2%和25.5%,OS率分别为50.0%和45.5%。
  • ECOG体能评分>1分为PFS的独立危险因素(多因素HR=7.971,P=0.001)。

核心结论

  • PEMD方案对初治早期非上呼吸道消化道或晚期ENKTL患者是安全有效的。

研究设计与样本

  • 回顾性分析纳入2016年1月至2022年12月于南京医科大学第一附属医院血液科诊断为初治早期非上呼吸道消化道或晚期ENKTL且接受PEMD方案诱导化疗的38例患者。
  • 采用Kaplan-Meier法计算PFS和OS率,Log-rank检验比较组间生存差异,进行生存和预后因素分析。

主要发现

  • 男30例(78.9%),女8例(21.1%);中位年龄48(26~72)岁;7例(18.4%)年龄>60岁。
  • 7例(18.4%)ECOG体能评分>1分,20例(52.6%)LDH水平升高,37例(97.4%)出现鼻部以外的结外组织受累,37例(97.4%)Ann Arbor分期为Ⅲ~Ⅳ期。
  • 中位治疗5(1~6)个周期,中位随访60(24~101)个月;治疗结束时总有效率为52.7%。
  • 2年和4年PFS率分别为34.2%(95% CI 22.0%~53.2%)和25.5%(95% CI 14.7%~44.4%),2年及4年OS率分别为50.0%(95% CI 36.4%~68.7%)及45.5%(95% CI 31.4%~65.7%)。
  • ECOG体能评分>1分[HR=3.711(95% CI 1.494~9.218),P=0.005]、骨髓浸润[HR=2.251(95% CI 1.026~4.938),P=0.043]及PINK-E评分3~5分[HR=2.350(95% CI 1.009~5.476),P=0.048]为PFS的危险因素;多因素分析ECOG体能评分>1分为PFS的独立危险因素[HR=7.971(95% CI 2.222~28.591),P=0.001]。

关键数值与推荐

  • 总有效率52.7%;2年PFS率34.2%(95% CI 22.0%~53.2%),4年PFS率25.5%(95% CI 14.7%~44.4%)。
  • 2年OS率50.0%(95% CI 36.4%~68.7%),4年OS率45.5%(95% CI 31.4%~65.7%)。
  • ECOG体能评分>1分:单因素HR=3.711(95% CI 1.494~9.218),P=0.005;多因素HR=7.971(95% CI 2.222~28.591),P=0.001。
  • 骨髓浸润:HR=2.251(95% CI 1.026~4.938),P=0.043;PINK-E评分3~5分:HR=2.350(95% CI 1.009~5.476),P=0.048。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of the pegaspargase, etoposide, methotrexate, and dexamethasone (PEMD) regimen in patients with early-stage nonupper respiratory digestive tract or advanced extranodal natural killer/T-cell lymphoma (ENKTL) . Methods: This retrospective analysis included 38 patients with newly diagnosed early-stage non-upper respiratory digestive tract or advanced ENKTL who received PEMD regimen for induction chemotherapy at the First Affiliated Hospital of Nanjing Medical University from January 2016 to December 2022. Survival outcomes and prognostic factors were examined by Kaplan-Meier, and the Log-rank test was used to compare survival. Results: The study population had a median age of 48 years (range, 26-72 years) and included 30 males (78.9%) and 8 females (21.1%). 7 patients' age >60 years (18.4%). The Eastern Cooperative Oncology Group (ECOG) performance score was >1 in 7 patients (18.4%) ; 20 patients (52.6%) had elevated lactate dehydrogenase levels; and 37 patients (97.4%) exhibited extranodal involvement. Using the Ann Arbor staging system, 37 patients (97.4%) were classified as stage Ⅲ-Ⅳ. The median number of treatment cycles was 5 (1-6), and the median follow-up duration was 60 months (24 - 101 months). Interim efficacy assessment revealed an overall response rate of 52.7%. At 2 and 4 years, the progression-free survival (PFS) rates were 34.2% (95% CI 22.0%-53.2%) and 25.5% (95% CI 14.7%-44.4%), respectively, and the overall survival rates were 50.0% (95% CI 36.4%-68.7%) and 45.5% (95% CI 31.4%-65.7%), respectively. The risk factors for worse PFS were ECOG performance score >1 [HR=3.711 (95% CI 1.494-9.218), P=0.005]; bone marrow infiltration [HR=2.251 (95% CI 1.026 - 4.938), P=0.043]; and Prognostic Index for Natural Killer/T-Cell Lymphoma score of 3 - 5 [HR=2.350 (95% CI 1.009 - 5.476), P=0.048]. Multivariate analysis identified ECOG performance score >1 as an independent risk factor for PFS [HR=7.971 (95% CI 2.222 - 28.591), P=0.001]. The main adverse effect was anemia in 31 patients (81.6%) . Conclusion: The PEMD regimen was safe and effective for patients with newly diagnosed early-stage non-upper respiratory digestive tract or advanced ENKTL. 目的: 探讨PEMD(培门冬酶+依托泊苷+甲氨蝶呤+地塞米松)方案治疗初治早期非上呼吸道消化道或晚期结外NK/T细胞淋巴瘤(ENKTL)患者的疗效及安全性。 方法: 回顾性分析纳入2016年1月至2022年12月于南京医科大学第一附属医院血液科诊断为初治早期非上呼吸道消化道或晚期ENKTL,且接受PEMD方案诱导化疗的38例患者。采用Kaplan-Meier法计算无进展生存(PFS)和总生存(OS)率,采用Log-rank检验比较组间生存差异,进行生存和预后因素分析。 结果: 男30例(78.9%),女8例(21.1%);中位年龄48(26~72)岁。7例(18.4%)年龄>60岁,7例(18.4%)美国东部肿瘤协作组(ECOG)体能评分>1分,20例(52.6%)LDH水平升高,37例(97.4%)出现鼻部以外的结外组织受累,37例(97.4%)Ann Arbor分期为Ⅲ~Ⅳ期。患者中位治疗5(1~6)个周期,中位随访时间为60(24~101)个月。所有患者治疗结束时的总有效率为52.7%。2年和4年的PFS率分别为34.2%(95% CI 22.0%~53.2%)和25.5%(95% CI 14.7%~44.4%),2年及4年OS率分别为50.0%(95% CI 36.4%~68.7%)及45.5%(95% CI 31.4%~65.7%)。ECOG体能评分>1分[HR=3.711(95% CI 1.494~9.218),P=0.005]、骨髓浸润[HR=2.251(95% CI 1.026~4.938,P=0.043)]及PINK-E评分3~5分[HR=2.350(95% CI 1.009~5.476),P=0.048]为PFS的危险因素,多因素分析ECOG体能评分> 1分为PFS的独立危险因素[HR=7.971(95% CI 2.222~28.591),P=0.001]。安全性评估显示,主要的不良反应为贫血(31例,81.6%)。 结论: PEMD方案对治疗初治早期非上呼吸道消化道或晚期ENKTL患者是安全有效的。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang XY, Du KX, Shen HR, et al. [Efficacy and safety of PEMD regimen in newly diagnosed early-stage non-upper respiratory digestive tract or advanced extranodal natural killer/T-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40134197. doi:10.3760/cma.j.cn121090-20241120-00463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。